Guggenheim Securities Initiates Coverage on HEARTWARE INTL INC COM(NASDAQ:HTWR). The shares have been rated Neutral. The rating by Guggenheim Securities was issued on Jun 9, 2016.
In a different note, On May 5, 2016, Leerink Swann said it Maintains its rating on HEARTWARE INTL INC COM. In the research note, the firm Lowers the price-target to $45.00 per share. The shares have been rated ‘Outperform’ by the firm. On Mar 24, 2016, Bank of America said it Upgrades its rating on HEARTWARE INTL INC COM. The shares have been rated ‘Buy’ by the firm.
HEARTWARE INTL INC COM (HTWR) shares turned negative on Wednesdays trading session with the shares closing down -0.26 points or -0.80% at a volume of 1,47,004. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $32.83. The peak price level was also seen at $32.83 while the days lowest was $31.99. Finally the shares closed at $32.07. The 52-week high of the shares is $94.15 while the 52-week low is $25.015. According to the latest information available, the market cap of the company is $563 M.
HEARTWARE INTL INC COM(HTWR) last announced its earnings results on May 4, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $55.07M. Analysts had an estimated revenue of $60.07M. Earnings per share were $-0.95. Analysts had estimated an EPS of $-0.77.
Several Insider Transactions has been reported to the SEC. On Apr 4, 2016, James Schuermann (SVP, Sales & Marketing) sold 1,000 shares at $31.36 per share price.Also, On Feb 26, 2016, Peter F Mcaree (SVP, CFO and Treasurer) sold 697 shares at $29.49 per share price.On Feb 26, 2016, Mark Strong (Senior VP, R&D and Quality) sold 395 shares at $29.67 per share price, according to the Form-4 filing with the securities and exchange commission.
Heartware International Inc. is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices for patients suffering from advanced heart failure. The HeartWare Ventricular Assist System (HVAD System) which includes a ventricular assist device (VAD) or blood pump patient accessories and surgical tools provides circulatory support for patients in the advanced stage of heart failure. The core of the HVAD System is a continuous flow blood pump the HVAD pump. The HVAD System is designed to be implanted adjacent to the heart avoiding abdominal surgery directly adjacent to the heart. The Company’s hybrid system is used for suspending the impeller. The impeller is suspended within the pump housing by the opposing forces of passive magnets and hydrodynamic thrust generated by the pump impeller which circulates a cushion of blood.